Jeremy Abramson, MD

Associate Professor
Harvard Medical School
Boston, MA

Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center, and Associate Professor of Medicine at Harvard Medical School.  Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School.  He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson’s clinical and research interests are in non-Hodgkin lymphomas, Hodgkin lymphoma, and CLL. His research involves identifying the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases.

Nazir Bahlis, MD, PhD

Associate Professor
University of Calgary
Charbonneau Cancer Research Institute
Division of Hematology and Oncology
Calgary, AB

Dr Bahlis is an Associate Professor of Medicine at the University of Calgary in the division of Hematology and Bone Marrow Transplantation and a member of the Charbonneau Cancer Research Institute. Dr Bahlis received his medical degree in 1995 from St Joseph University – French Faculty of Medicine in Beirut. He then completed his internal Medicine residency at the State University of New York in Syracuse followed by a Hematology-Oncology fellowship at the University of Miami, Florida. Dr Bahlis also completed a postdoctoral fellowship in cancer biology at the University of Miami under the mentorship of Dr Lawrence Boise. Dr Bahlis’ clinical and laboratory research focus on the study of plasma cell dyscrasia, with particular interest in multiple myeloma genomics and the development of novel therapeutics. He has received several awards and research funding from numerous agencies including the ASCO young investigator award, the Multiple Myeloma Research Foundation, The Leukemia and Lymphoma Society of Canada, Alberta Cancer Foundation, the National Institute of Health, the Terry Fox Foundations and the Canadian Institute of Health and Research (CIHR). His research work was published in many peer-reviewed journals including New England Journal of Medicine, Blood, Leukemia, Molecular Cancer Research and Clinical Cancer Research. Dr Bahlis also served on the editorial board for the journal Blood and on the review panels of several national and international funding agencies.  He is a member of the American Society of Hematology (ASH), the ASH plasma cell dyscrasia scientific panel and the international myeloma society (IMS) education panel.

Matthew Davids, MD

Professor of Medicine
Harvard Medical School
Boston, MA

After obtaining an A.B. in chemistry at Harvard College, Dr. Davids completed his M.D. at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then
completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (M.M.S.c.) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves at the Director of Clinical Research, as well as Associate Director of the CLL Center. He is
also an Associate Professor of Medicine at Harvard Medical School, and attends on the inpatient hematologic malignancies service at Brigham & Women’s Hospital. Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading
clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint
blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.

Philippe Moreau, MD

Professor of Clinical Hematology
Head, Translational Research Prog. Hematology & Oncology
University Hospital of Nantes
Nantes, FR

Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology, at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.

Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM) since 2020.

He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator of several international clinical trials evaluating Carfizomib, Ixazomib, Venetoclax, Daratumumab, Isatuximab, or Teclistamab. He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.

His research is widely published, with more than 500 peer-reviewed articles and reviews that have appeared in high impact factor journals (94 times first/senior author in IF journals>6) including New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, and Blood (64 highly cited papers and 1 hot papers). He has been listed into the Clarivate Analytics (2017-2022), list of world-class highly cited researchers, that rank in the top 1% by citations for field and year in Web of Science and at the top of the world’s expertise in multiple myeloma (2021-2022, https://expertscape.com/ex/multiple+myeloma), based on 18,933 eligible articles published since 2012. He is frequently invited speaker at international hematologic oncology meetings, and during Educational Session on Multiple Myeloma at ASH, ASCO or EHA.

Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.

Paola Neri, MD, PhD

Associate Professor of Medicine
University of Calgary
Arnie Charbonneau Cancer Institute
Calgary, AB

Dr. Paola Neri, MD, PhD is an Associate Professor of Medicine, attending physician in the Hematology division at University of Calgary and member of the Arnie Charbonneau Cancer Institute. Since January 2019 she is the Scientific Director of the Precision Oncology Hub, Translational Research Laboratory, at the Tom Baker Cancer Centre (TBCC) in Calgary.

Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011.  From 2003-2006 she was Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA under the mentorship of Dr. Kenneth Anderson. In June 2008, she joined the University of Calgary.

The main focus of her research is the study of multiple myeloma (MM) with a particular interest in drug development and genomic studies with the goal of discovering novel therapeutic targets for this incurable disease. As such she has investigated the genome signature associated with MM cell response or resistance to anti-MM agents to identify druggable therapeutic targets in MM and new biomarkers of response to novel agents.

Dr. Neri is well published in the field and received national and international grants from several agencies including International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and Canadian Institute of Health Research (CIHR).  In 2021 she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her impressive translational work in multiple myeloma.

She is currently member of the American Society of Hematology and the scientific board of Myeloma Canada, very active both in preclinical and clinical trial research in Myeloma.

Constantine Tam, MD, FRACP, FRCPA

Professor of Haematology
Monash University
Head of Lymphoma Service
Alfred Health
Melbourne, AU

Professor Constantine (Con) Tam is Head of Lymphoma Service at Alfred Health, and Professor of Haematology at Monash University. Con received his M.B.B.S.(Hons) and M.D. degrees from the University of Melbourne. After dual training in Haematology and Haematopathology, Con completed his Leukemia Fellowship at MD Anderson Cancer Centre in Houston, Texas. Prior to moving to the Alfred, Con served as Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre & Royal Melbourne Hospital for over 10 years.

Con is passionate about developing new treatment for blood cancers. He is the global lead for the BTK inhibitor zanubrutinib, and oversaw its development from the first human dosed (in Melbourne) to successful international licensing studies worldwide. Con designed and performed the first global study to combine ibrutinib and venetoclax, publishing the results in the New England Journal of Medicine 5 years after inception. In 2015, he became the Australian lead for the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma, leading to public funding for CAR T-cells as standard treatment in Australia.

The publication record for Con includes 259 peer-reviewed papers in New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Blood and other top-tier journals. His work has been cited >18,000 times in the literature. Con is Associate Editor for Blood Advances.

Julie Vose, MD, MBA, FASCO

Professor
Chief, Hematology/Oncology
University of Nebraska Medical Center
Omaha, NB

Dr. Vose is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at UNMC which includes 32 physicians specializing in Medical Hematology/Oncology. Dr. Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at UNMC. Dr. Vose also completed a sabbatical at Stanford University.   In addition, she completed an MBA in Health Administration through the University of Colorado Business School.  Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL), Hodgkin lymphoma (HL), and Chronic Lymphocytic Leukemia (CLL) by developing a focused translational research program evaluating novel therapies such as monoclonal antibodies, immunotherapy, pathway directed agents, stem cell transplantation, and chimeric antigen receptor T-cell (CAR-T) treatments. Dr. Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma.  She has published over 400 manuscripts in peer reviewed journals.  She was the 2015-16 President of the American Society of Clinical Oncology (ASCO), the largest international society of health care professionals who perform research and treat cancer.